Table 3.
Antimicrobial susceptibility in Shigella isolates from ill children inYucatan, Mexico, 2005–2011. Percentage of resistance*.
| Year of isolation | AMP | CRO | AZT | CIP | NAL | CHL | FZD† | STX | TET |
|---|---|---|---|---|---|---|---|---|---|
| 2005–2006 (n = 73) | 39.8 | 0 | 0 | 0 | 0 | 16.4 | 57.5 | 57.5 | 83.6 |
| 2007–2009 (n = 79) | 44.3 | 0 | 0 | 0 | 1.3 | 24.1 | 25.4 | 59.5 | 92.4 |
| 2010–2011 (n = 66) | 34.8 | 0 | 0 | 0 | 0 | 12.1 | 25.8 | 59.0 | 93.9 |
AMP, ampicillin; AZT, azithromycin; CAZ, ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; FZD, furazolidone; GEN, gentamicin; NAL, nalidixic acid, STX, trimethoprim–sulfamethoxazole; TET, tetracycline.
*
Includes resistant and intermediate strains.
†
Difference from 2005 to 2011: p < 0.001.